Landos Biopharma — Technical Presentation (August 2022)
16 slides from Landos Biopharma's technical presentation, Aug 11, 2022
Slide 1: NX-13 Phase 1b Clinical Trial Data
NX-13 Phase 1b Clinical Trial Data AUGUST 2022 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our strategy, future operations, prospects, pla
Slide 3: Positive Top-Line Results Highlight Strong Company Momentum
Positive Top-Line Results Highlight Strong Company Momentum NX-13 PH. 1b in UC *Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only. Support potential of NX-13 as important, new treatment for Ulcerative Colitis (UC) Validate sharpened
Slide 4: Roadmap for NX-13 Development
Roadmap for NX-13 Development What’s next: Announcing timing and study design for Phase 2 proof of concept trial later this year What we learned in the Phase 1b trial: What we still need to determine: Favorable safety profile and tolerability in active UC across the study Indications of clinical imp
Slide 5: Phase 1b Clinical Trial Data
NX-13 Phase 1b Clinical Trial Data
Slide 6: NX-13 Overview and Mechanism of Action
NX-13 Overview Mechanism of Action Drug Profile Recent & Upcoming Milestones Targets NLRX1 pathway, a mitochondrial-associated regulatory NOD-like receptor Orally active and gut-restricted, allowing target engagement within the GI tract Recently completed successful Phase 1b trial Announcing timing
Slide 7: Selectively Targets Novel Target NLRX1 in the Gut
NX-13 Selectively Targets Novel Target NLRX1 in the Gut
Slide 8: Phase 1b Study Design of NX-13 in Active UC
Phase 1b Study Design of NX-13 in Active UC Primary Objective: To assess the safety and tolerability of NX-13 after multiple oral dose administration in subjects with active ulcerative colitis (UC) Key Inclusion Criteria: Male and female subjects 18-75 years old; Active UC >90days; Total Mayo Score
Slide 9: Phase 1b Study Design of NX-13 in Active UC
Phase 1b Study Design of NX-13 in Active UC Group 1: NX-13 250mg IR n=12 Group 4: Placebo n = 4 Week 2 Week 4 EOT Group 3: NX-13 500 mg MR n=12 Week 5 post-treatment Week 2 Week 4 EOT Week 5 post-treatment Week 2 Week 4 EOT Week 5 post-treatment Week 2 Week 4 EOT Week 5 post-treatment Group 2: NX-13
Slide 10: NX-13 Well-Tolerated and Shows Promising Efficacy Signals in Active UC
NX-13 was Well-Tolerated and Shows Promising Efficacy Signals in Active UC *Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Safety: NX-13 was generally well tolerated, consistent with non-clinical, Phase 1a data Pharmacokinetics:
Slide 11: NX-13 Phase 1b Trial Safety Evaluations
Subjects with Placebo (n = 4) NX-13 250mg (n=11) NX-13 500mg (n=10) NX-13 500mg MR (n=11) Serious AEs 0 0 0 0 Mild/Moderate TEAEs 1 (20%) 2 (18.2%) 3 (27.3%) 6 (54.5%) GI (abdominal pain, UC worsening, pancreatitis, constipation) 1 (20%) 0 1 (9.1%) 3 (27.3%) Renal (congenital PCKD, increased creatin
Slide 12: Total Mayo Score Change from Baseline
Total Mayo Score Change from Baseline Clinical Response Defined as CFB of -3, or -30% in Mayo Score Clinical Remission Defined as Mayo Score less than 2, with no subscore above 1 NX-13 Treated Patients Experienced Reductions in Total Mayo Score after 4 weeks IR= Immediate Release; MR= modified relea
Slide 13: Mayo Endoscopy Score Change from Baseline
Mayo Endoscopy Score Change from Baseline Endoscopic Response (MES CFB -1) Endoscopic Improvement at All Doses Driving Reduction of Mayo Score FCP = Fecal Calprotectin; Normalization defined as an FCP score reduction to below 250. MES = Mayo Endoscopy Score; PROs = Patient Reported Outcomes *Study w
Slide 14: Supported Symptomatic Remission in Rectal Bleeding and Stool Frequency
NX-13 Supported Symptomatic Remission in Rectal Bleeding and Stool Frequency Patients in the 250mg group had the greatest reduction of Rectal Bleeding and Stool Frequency at 2 weeks, with further reduction at 4 weeks Majority of patients saw complete resolution of BOTH rectal bleeding and stool freq
Slide 15: Fecal Calprotectin (FCP) Change and Normalization
Week 4 FCP Change from Baseline FCP Normalization (FCP decrease to <250) Fecal Calprotectin (FCP) Change and Normalization FCP = Fecal Calprotectin; Normalization defined as an FCP score reduction to below 250. *Study was not designed or powered for exploratory clinical endpoints therefore results a
Slide 16: NX-13 Well-Tolerated and Shows Promising Efficacy Signals in Active UC
NX-13 was Well-Tolerated and Shows Promising Efficacy Signals in Active UC *Study was not designed or powered for exploratory clinical endpoints therefore results are hypothesis-generating only Safety: NX-13 was generally well tolerated, consistent with non-clinical, Phase 1a data Pharmacokinetics:
Landos Biopharma — Technical Presentation (August 2022) on 6ix